loading
前日終値:
$107.01
開ける:
$106.25
24時間の取引高:
509.46K
Relative Volume:
0.66
時価総額:
$8.51B
収益:
$51.48M
当期純損益:
$-315.00M
株価収益率:
-28.96
EPS:
-3.5708
ネットキャッシュフロー:
$-244.00M
1週間 パフォーマンス:
-6.48%
1か月 パフォーマンス:
-9.83%
6か月 パフォーマンス:
+42.25%
1年 パフォーマンス:
+136.34%
1日の値動き範囲:
Value
$102.13
$106.72
1週間の範囲:
Value
$102.13
$113.00
52週間の値動き範囲:
Value
$36.65
$130.05

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1079)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
253
Name
Twitter
Name
次回の収益日
2026-08-10
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
103.40 9.05B 51.48M -315.00M -244.00M -3.5708
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-05-06 開始されました Canaccord Genuity Buy
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Jul 28, 2026

KYMR Maintained by Guggenheim -- Price Target Raised to $135 - GuruFocus

Jul 28, 2026
pulisher
Jul 28, 2026

Guggenheim raises Kymera Therapeutics price target on IRF5 program By Investing.com - Investing.com Canada

Jul 28, 2026
pulisher
Jul 27, 2026

KYMR Looks 356.6% Overvalued on GF Value™ - GuruFocus

Jul 27, 2026
pulisher
Jul 27, 2026

Form 4 Kymera Therapeutics Inc For: 27 July By Investing.com - Investing.com South Africa

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer - Investing News Network

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics names Terence Rooney as chief medical officer - Investing.com

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics names Terence Rooney as new Chief Medical Officer to lead clinical development. - Pluang

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics (NASDAQ: KYMR) names Terence Rooney as new CMO - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Johnson & Johnson Immunology Leader Joins Kymera as Chief Medical Officer - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics officers probed for possible self-dealing, shareholders urged to act. - Pluang

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics Inc (KYMR) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Kymera Therapeutics Inc (KYMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Kymera Therapeutics Inc (KYMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 26, 2026
pulisher
Jul 24, 2026

KYMR|Kymera Therapeutics Inc|Price:110.570|Chg%:+0.190 - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

KYMR|Kymera Therapeutics Inc|Price:110.320|Chg%:-0.250 - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Is Kymera Therapeutics Poised for a Breakthrough With KT-621? - Yahoo Finance

Jul 24, 2026
pulisher
Jul 24, 2026

Kymera Therapeutics Inc (KYMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 21, 2026

💪💪💪💪💪💪💪💪💪💪💪 - Moomoo

Jul 21, 2026
pulisher
Jul 21, 2026

Kymera Therapeutics stock slips to $111.06 amid selling pressure and volatile trading - Traders Union

Jul 21, 2026
pulisher
Jul 21, 2026

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Promising Biotech with a 12.68% Upside - DirectorsTalk Interviews

Jul 21, 2026
pulisher
Jul 19, 2026

(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jul 19, 2026
pulisher
Jul 17, 2026

Law firm probes Kymera Therapeutics' officers f... - Pluang

Jul 17, 2026
pulisher
Jul 16, 2026

KYMR Maintained by Mizuho -- Price Target Raised to $140 - GuruFocus

Jul 16, 2026
pulisher
Jul 16, 2026

Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo

Jul 16, 2026
pulisher
Jul 16, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire

Jul 16, 2026
pulisher
Jul 16, 2026

Kymera Therapeutics Price Target Raised to $140.00/Share From $120.00 by Mizuho - Moomoo

Jul 16, 2026
pulisher
Jul 16, 2026

Mizuho Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $140 - Moomoo

Jul 16, 2026
pulisher
Jul 16, 2026

Kymera Therapeutics (KYMR) AGM 2024 Summary - Quartr

Jul 16, 2026
pulisher
Jul 16, 2026

Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary - Quartr

Jul 16, 2026
pulisher
Jul 16, 2026

Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr

Jul 16, 2026
pulisher
Jul 13, 2026

Form 144 Kymera Therapeutics For: 13 July By Investing.com - Investing.com Nigeria

Jul 13, 2026
pulisher
Jul 13, 2026

RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from "outperform" to "sector perform." - Bitget

Jul 13, 2026
pulisher
Jul 13, 2026

Kymera Therapeutics Shares Fall After RBC Downgrade - Moomoo

Jul 13, 2026
pulisher
Jul 13, 2026

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk - marketscreener.com

Jul 13, 2026
pulisher
Jul 12, 2026

Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Globe and Mail

Jul 12, 2026
pulisher
Jul 12, 2026

Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Motley Fool

Jul 12, 2026
pulisher
Jul 12, 2026

BTIG maintains Kymera Therapeutics (KYMR) buy recommendation - MSN

Jul 12, 2026
pulisher
Jul 09, 2026

Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN

Jul 09, 2026
pulisher
Jul 09, 2026

Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey

Jul 09, 2026
pulisher
Jul 08, 2026

Kymera jumps 17% on early enrollment completion in skin disease study - MSN

Jul 08, 2026
pulisher
Jul 08, 2026

Kymera's High-Flying Stock Meets Insider Selling - Kavout | AI

Jul 08, 2026
pulisher
Jul 08, 2026

Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey

Jul 08, 2026
pulisher
Jul 08, 2026

Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com

Jul 08, 2026
pulisher
Jul 08, 2026

Kymera Therapeutics (KYMR) Citi's Biopharma Back to School Conference Summary - Quartr

Jul 08, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Canada

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com

Jul 07, 2026
pulisher
Jul 07, 2026

Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com

Jul 07, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Kymera Therapeutics Inc (KYMR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Mainolfi Nello
Chief Executive Officer
Jul 07 '26
Sale
119.00
50,000
5,950,000
666,568
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):